HIV-1 Protease Dimerization Dynamics Reveals a Transient Druggable Binding Pocket at the Interface

The binding mechanism of HIV-1 protease monomers leading to the catalytically competent dimeric enzyme has been investigated by means of state-of-the-art atomistic simulations. The emerging picture allows a deeper understanding of experimental observations and reveals that water molecules trapped at the interface have an important role in slowing down the kinetics of the association process. Unexpectedly, a cryptic binding pocket is identified at the interface of the complex, corresponding to a partially bound dimer that lacks enzymatic function. The pocket has a transient nature with a lifetime longer than 1 μs, and it displays very favorable druggability features. Docking as well as MM-GBSA free-energy calculations further support the possibility to target the new binding site by means of inhibitors able to prevent the complete dimerization by capturing the inactive conformation. This discovery could open the way to the rational design of a new class of anti-HIV drugs.

[1]  C. Matthews,et al.  The folding free-energy surface of HIV-1 protease: insights into the thermodynamic basis for resistance to inhibitors. , 2009, Journal of molecular biology.

[2]  Bert L. de Groot,et al.  Ligand docking and binding site analysis with PyMOL and Autodock/Vina , 2010, J. Comput. Aided Mol. Des..

[3]  Amedeo Caflisch,et al.  Flexibility of monomeric and dimeric HIV-1 protease , 2003 .

[4]  J Andrew McCammon,et al.  Discovery of a novel binding trench in HIV integrase. , 2004, Journal of medicinal chemistry.

[5]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[6]  P. Ruggerone,et al.  Different molecular mechanisms of inhibition of bovine viral diarrhea virus and hepatitis C virus RNA-dependent RNA polymerases by a novel benzimidazole. , 2013, Biochemistry.

[7]  D. Case,et al.  Molecular Dynamics Simulations of Nucleic Acids with a Generalized Born Solvation Model , 2000 .

[8]  Amedeo Caflisch,et al.  How Does Darunavir Prevent HIV-1 Protease Dimerization? , 2012, Journal of chemical theory and computation.

[9]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[10]  Arun K. Ghosh,et al.  In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors , 2010, Journal of Virology.

[11]  X. Barril,et al.  Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. , 2010, Journal of medicinal chemistry.

[12]  Paolo Carloni,et al.  Conformational flexibility of the catalytic Asp dyad in HIV‐1 protease: An ab initio study on the free enzyme , 2000, Proteins.

[13]  Peter A. Kollman,et al.  Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models , 2001 .

[14]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[15]  Holger Gohlke,et al.  MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.

[16]  A. Lisitsa,et al.  Kinetic and thermodynamic analysis of dimerization inhibitors binding to HIV protease monomers by surface plasmon resonance , 2012, Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry.

[17]  Vincent Le Guilloux,et al.  Fpocket: An open source platform for ligand pocket detection , 2009, BMC Bioinformatics.

[18]  Irene T. Weber,et al.  Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[19]  Jacob D. Durrant,et al.  Molecular dynamics simulations and drug discovery , 2011, BMC Biology.

[20]  M. Parrinello,et al.  Multiple Routes and Milestones in the Folding of HIV–1 Protease Monomer , 2010, PloS one.

[21]  D. Ho,et al.  Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor , 1997, Antimicrobial agents and chemotherapy.

[22]  G. Bowman,et al.  Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites , 2012, Proceedings of the National Academy of Sciences.

[23]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[24]  T. M. Raschke,et al.  Water structure and interactions with protein surfaces. , 2006, Current opinion in structural biology.

[25]  J. Konvalinka,et al.  Current and Novel Inhibitors of HIV Protease , 2009, Viruses.

[26]  E. Freire,et al.  The structural stability of the HIV-1 protease. , 1998, Journal of molecular biology.

[27]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[28]  A. Laio,et al.  Substrate binding mechanism of HIV-1 protease from explicit-solvent atomistic simulations. , 2009, Journal of the American Chemical Society.

[29]  D. Case,et al.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. , 2003, Journal of molecular biology.

[30]  A. Roitberg,et al.  pH-REMD simulations indicate that the catalytic aspartates of HIV-1 protease exist primarily in a monoprotonated state. , 2014, The journal of physical chemistry. B.

[31]  Masayuki Amano,et al.  Potent Inhibition of HIV-1 Replication by Novel Non-peptidyl Small Molecule Inhibitors of Protease Dimerization* , 2007, Journal of Biological Chemistry.

[32]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[33]  A. Vargiu,et al.  Detecting DNA mismatches with metallo-insertors: a molecular simulation study. , 2012, Inorganic chemistry.

[34]  Asim Okur,et al.  Improving the description of salt bridge strength and geometry in a Generalized Born model. , 2011, Journal of molecular graphics & modelling.

[35]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[36]  B. Berne,et al.  Dewetting and hydrophobic interaction in physical and biological systems. , 2009, Annual review of physical chemistry.

[37]  H. Mitsuya,et al.  Loss of the Protease Dimerization Inhibition Activity of Tipranavir (TPV) and Its Association with the Acquisition of Resistance to TPV by HIV-1 , 2012, Journal of Virology.

[38]  Shantenu Jha,et al.  Computing Clinically Relevant Binding Free Energies of HIV-1 Protease Inhibitors , 2014, Journal of chemical theory and computation.

[39]  J. Louis,et al.  Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps , 2014, ACS chemical biology.

[40]  Attilio V Vargiu,et al.  Multidrug binding properties of the AcrB efflux pump characterized by molecular dynamics simulations , 2012, Proceedings of the National Academy of Sciences.

[41]  F. Gago,et al.  Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes? , 2006, Antiviral research.

[42]  Maria Paola Costi,et al.  Homodimeric enzymes as drug targets. , 2010, Current medicinal chemistry.

[43]  Massimiliano Bonomi,et al.  PLUMED: A portable plugin for free-energy calculations with molecular dynamics , 2009, Comput. Phys. Commun..

[44]  T. Cheatham,et al.  Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations , 2008, The journal of physical chemistry. B.

[45]  Paolo Carloni,et al.  On the nature of the reaction intermediate in the HIV-1 protease: a quantum chemical study , 2008, Comput. Phys. Commun..

[46]  L. M. Amzel,et al.  Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance Mutations , 2007, Journal of Virology.

[47]  G. Clore,et al.  Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease , 2008, Nature.

[48]  P. Kollman,et al.  Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .

[49]  A. Laio,et al.  A bias-exchange approach to protein folding. , 2007, The journal of physical chemistry. B.

[50]  Tamaria G. Dewdney,et al.  The higher barrier of darunavir and tipranavir resistance for HIV-1 protease. , 2011, Biochemical and biophysical research communications.

[51]  J. Louis,et al.  Characterization of two hydrophobic methyl clusters in HIV-1 protease by NMR spin relaxation in solution. , 2001, Journal of molecular biology.

[52]  A. Bondi.  van der Waals Volumes and Radii , 1964 .

[53]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[54]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[55]  Arun K. Ghosh,et al.  Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir , 2014, Proceedings of the National Academy of Sciences.

[56]  Jörg Weiser,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999, J. Comput. Chem..

[57]  Alessandro Laio,et al.  A Kinetic Model of Trp-Cage Folding from Multiple Biased Molecular Dynamics Simulations , 2009, PLoS Comput. Biol..

[58]  A Wlodawer,et al.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.

[59]  J. Louis,et al.  Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. , 1999, Structure.

[60]  I D Kuntz,et al.  Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. , 1997, The Journal of biological chemistry.

[61]  Carlos Simmerling,et al.  Improved Generalized Born Solvent Model Parameters for Protein Simulations. , 2013, Journal of chemical theory and computation.

[62]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[63]  P. Ruggerone,et al.  Molecular mechanism of viral resistance to a potent non-nucleoside inhibitor unveiled by molecular simulations. , 2014, Biochemistry.

[64]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[65]  Alessandro Laio,et al.  METAGUI. A VMD interface for analyzing metadynamics and molecular dynamics simulations , 2012, Comput. Phys. Commun..

[66]  A. Brigo,et al.  The Poisson–Boltzmann equation for biomolecular electrostatics: a tool for structural biology , 2002, Journal of molecular recognition : JMR.

[67]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[68]  Arun K. Ghosh,et al.  Critical differences in HIV‐1 and HIV‐2 protease specificity for clinical inhibitors , 2012, Protein science : a publication of the Protein Society.

[69]  J. Konvalinka,et al.  Thermodynamic and structural analysis of HIV protease resistance to darunavir – analysis of heavily mutated patient‐derived HIV‐1 proteases , 2014, The FEBS journal.

[70]  Rommie E. Amaro,et al.  Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53 , 2013, Nature Communications.

[71]  R. Broglia,et al.  The maturation of HIV‐1 protease precursor studied by discrete molecular dynamics , 2014, Proteins.

[72]  Daniel Kuhn,et al.  Combining Global and Local Measures for Structure-Based Druggability Predictions , 2012, J. Chem. Inf. Model..

[73]  Harry Jubb,et al.  Structural biology and drug discovery for protein-protein interactions. , 2012, Trends in pharmacological sciences.